A PHASE 3B, OPEN LABEL, CONTROLLED, MULTI CENTER, EXTENSION STUDY TO ASSESS THE PERSISTENCE OF BACTERICIDAL ACTIVITY AT 4 TO 7.5 YEARS AFTER TWO DOSE PRIMARY SERIES OF NOVARTIS MENINGOCOCCAL B RECOMBINANT VACCINE AND THE RESPONSE TO A THIRD DOSE IN ADOLESCENTS AND YOUNG ADULT SUBJECTS WHO PREVIOUSLY PARTICIPATED IN PARENT STUDIES V72_41 AND V72PI0, COMPARED TO NAIVE HEALTHY CONTROLS

Registry ID
V72_75
Source registry
HEALTH_CANADA
Status
Ongoing
Phase
PHASE3
Study type
INTERVENTIONAL
Sponsor
NOVARTIS VACCINES AND DIAGNOSTICS INC
Start date
2015-11-05
Last update
2015-09-17

Conditions

Related clinical trials

View on source registry